INTRODUCTION
============

Vanilloid receptor 1 (VR1), also known as transient receptor potential cation channel subfamily V member 1, is a non-selective cation channel that is predominantly expressed by sensory neurons of dorsal root and trigeminal ganglia ([@B1]). VR1 is activated by a diverse chemical ligands such as capsaicin (CP), resiniferatoxin (RTX), allyl isothiocyanate, and anandamide, as well as by temperatures greater than 43℃ ([@B2][@B3][@B4]). VR1 activation leads to a painful, burning sensation. CP, the pungent component of hot peppers, is the best known VR1 agonist ([@B5]). RTX is an irritant component of a cactus-like plant, *Euphorbia resinifera* ([@B6]). CP and RTX activate and then desensitize VR1. RTX is much more potent than CP in inducing analgesia ([@B2][@B7]).

CP can modulate many parameters of immune responses. CP was shown to inhibit Con-A-induced lymphocyte proliferation ([@B8]); the production of cytokines such as GM-CSF, IFN-γ, and IL-2 from PMA-activated Jurkat T cells ([@B9]); prostaglandin E2 (PGE~2~) and NO production in LPS-stimulated peritoneal macrophages ([@B10]); LPS- and IFN-γ-mediated NO production, iNOS protein and mRNA expression, and LPS- and PMA- induced COX-2 expression and PGE~2~ production in RAW264.7 macrophages ([@B11]); T cell differentiation in neonatal rats ([@B12]); and the accumulation of DCs and other inflammatory cells around small pulmonary vessels during the pulmonary response to inhaled antigens in rats ([@B13]). Some of the diverse immunomodulatory activities of CP are due to its binding to VR1 on DCs. DCs, like the sensory neurons, express VR1 ([@B14][@B15]). CP was shown to induce the maturation of immature DCs in VR1^+^/^+^ mice, but not in VR1^--^/^--^ mice ([@B14]). In addition, intradermal CP injection induced DC migration to the draining lymph nodes in VR1^+^/^+^ mice, but not in VR1^--^/^--^ mice ([@B14]). CP also increased the capability of exogenous antigen presentation in association with MHC class I molecules in the DCs of VR1^+^/^+^ mice, but not of VR1^--^/^--^ mice. In contrast to the promotion of MHC class I-restricted exogenous antigen presentation, CP inhibited MHC class II-restricted exogenous antigen presentation by suppressing transcription of class II transactivator genes in murine peritoneal macrophages ([@B16]).

In the present study, we showed that CP and RTX increased MHC class I-restricted presentation of virus-encoded endogenous antigens in DCs, both *in vitro* and *in vivo*, and enhanced viral antigen-specific CTL activity in virus-infected mice. These results demonstrate a neuro-immune connection in anti-viral immune responses and also imply that the oral consumption of CP, a pungent component of pepper, could be useful in enhancing anti-viral CTL responses.

MATERIALS AND METHODS
=====================

Cell lines, reagents, and mice
------------------------------

A T cell hybridoma, B3Z86/90.14 (B3Z), was provided by Dr. Nilabh Shastri (University of California, Berkeley, CA, USA) ([@B17]). The T cell hybridomas, CD8 OVA1.3 and DOBW, were provided by Dr. Clifford V. Harding (Case Western Reserve University, Cleveland, OH, USA) ([@B18][@B19]). Recombinant vaccinia virus encoding OVA (VV-OVA) was provided by Dr. Jonathan W. Yewdell (National Institutes of Health, Bethesda, MD, USA) ([@B20]). Both capsaicin (CP) and resiniferatoxin (RTX) were purchased from Sigma-Aldrich (St. Louis, MO, USA). The compounds were dissolved in absolute ethanol for *in vitro* experiments or in ethanol/tween-20/PBS (10/10/80) for *in vivo* experiments. Male, C57BL/6 and BALB/c mice (8\~12-week-old) were purchased from Orient Co., Ltd. (Seoul, Korea). Mice were studied according to the protocols approved by the Animal Care Committee of Chungbuk National University.

Generation of bone marrow-derived DCs (BM-DCs)
----------------------------------------------

BM-DCs were generated as described previously ([@B21]). Briefly, total BM cells obtained from mouse femurs were cultured in 6-well plates (5×10^6^/well) in culture medium containing 40 ng/ml GM-CSF and 20 ng/ml IL-4 (both from CreaGene, Seongnam, Korea). After 3 and 4 days, non-adherent cells were removed by gentle shaking and replacing the medium. Immature BM-DCs were harvested by gentle pipetting on day 6.

*In vitro* viral antigen-presentation assay
-------------------------------------------

Immature BM-DCs (1×10^7^/ml) were infected with VV-OVA (multiplicity of infection \[MOI\]=5) for 20 min at 37℃. Virus-infected DCs were diluted to 1×10^6^/ml with DMEM containing 10% FBS and 1 µM cytosine β-D-arabinofuranoside (Sigma-Aldrich), and distributed to a 96-well microtiter plate (100 µl/well). After adding the indicated quantities of VR1 agonists, the plate was incubated for 6 h at 37℃. After fixing the cells with ice-cold, 1.0% paraformaldehyde for 5 min at room temperature, class I MHC-complexed OVA peptide quantities were assessed using CD8 OVA 1.3 cells (2×10^5^/well), which recognize OVA\[257-264\]-K^b^ complexes and secrete IL-2 ([@B22]).

VR1 agonist treatment and VV-OVA infection
------------------------------------------

C57BL/6 (H-2^b^) mice were orally administrated CP (10 mg/kg) or RTX (0.1 mg/kg) for 3 days, and then infected with VV-OVA (5×10^4^ CFUs/mouse, i.v. administration). After infection, the mice were orally administered the same doses of CP or RTX for 5 consecutive days. On the final day of final VR1 agonist administration, functional assays were performed, such as the *in vivo* antigen-presentation assay, *in vivo* CTL assay, and OT-I T cell-adaptive transfer assay were performed.

*In vivo* viral antigen-presentation assay
------------------------------------------

DCs were isolated from the lymph nodes (popliteal, inguinal, mesenteric, and axillary) and spleens were collected and pooled (≥10 mice per treatment group), using a negative-selection method, as described previously ([@B23]). Class I-restricted T cell activation assays were then performed as described previously ([@B17]) using B3Z cells, which express β-galactosidase when activated with OVA\[257-264\]-K^b^ complexes. The B3Z cell responses were determined by X-gal (5-bromo-4-chloro-3-indoyl-β- D-galactopyranoside) staining ([@B23]).

Phenotype analysis
------------------

Cells were stained with mAbs recognizing murine cell surface markers as described previously ([@B22]), and flow cytometric analysis was performed on a FACS Canto II (BD Biosciences, San Jose, CA, USA). mAbs (anti-H2-K^b^, anti-I-A^b^, anti-CD80, anti-CD86, and an isotype-matched control) were purchased from BD Biosciences. The mAbs recognizing OVA\[257-264\]-K^b^ complexes, Alexa 488-conjugated 25-D1.16, was kindly provided by Dr. Jonathan W. Yewdell (National Institutes of Health, Bethesda, MD) ([@B20]).

*In vivo* CTL assay
-------------------

*In vivo* evaluation of the cytotoxic activities was performed using 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE, Molecular Probes)-labeled target cells prepared from syngeneic spleen and lymph node cell suspensions, as described previously ([@B23]). Specific *in vivo* cytotoxicity was determined for the lymph node and spleen cells isolated from the recipient mice 18 h after the i.v. injection of target cells. The ratio between the percentage of uncoated vs. OVA\[257-264\]-coated (CFSE^low^/CFSE^high^) cells was calculated to obtain a numerical value of the cytotoxicity.

OT-I T cell transfer experiment
-------------------------------

CD8^+^ T cells were isolated from the pooled spleens and lymph nodes of OT-I mice using a CD8^+^ T Cell Isolation kit (Miltenyi Biotec Inc., Auburn, CA, USA). The cells were labelled with 50 µM CFSE, and injected into the tail vein of mice (1×10^7^ cells/mouse). After 4 days, proliferation of CFSE-labeled OT-I CD8^+^ T cells was determined for the lymph node and spleen cells isolated from the recipient mice by flow cytometry.

Intracellular IFN-γ staining
----------------------------

Intracellular IFN-γ staining was performed as described previously ([@B24]) using a FITC-labeled anti-CD8 mAb and a PE-conjugated anti-IFN-γ mAb (BD Biosciences) ([@B24]). Cells were then analyzed using a FACSCanto II flow cytometer (BD Biosciences), and the number of CD8^+^ cells expressing IFN-γ was enumerated using FlowJo software (TreeStar, Ashland, OR, USA).

Preparation of microspheres containing OVA (OVA-microspheres)
-------------------------------------------------------------

OVA-microspheres were prepared using a homogenization/ solvent evaporation method, as described previously ([@B21]), with 400 µl of OVA-containing water (50 mg OVA/ ml) and 2 ml of ethyl acetate containing poly(lactic-coglycolic acid) (100 mg/ml, Sigma-Aldrich). Fluorescent microspheres were prepared by adding FITC (5 µg/ml) to the ethyl acetate phase.

Exogenous antigen-presentation assays
-------------------------------------

BM-DCs, generated from the BM cells of C57BL/6 or BALB/c mice, were seeded in 96-well microtiter plates (1×10^5^/well) in the presence of different concentrations of CP or RTX, incubated for 4 h at 37℃, and then OVA-microspheres (50 µg/ml as OVA) were added. After 2 h incubation at 37℃, the cells were fixed with 1.0% paraformaldehyde for 5 min at room temperature. Class I MHC-complexed OVA peptide quantities were assessed using CD8 OVA 1.3 cells (2×10^5^/well), which recognize OVA\[257-264\]-K^b^ complexes and secrete IL-2 ([@B22]). Class II MHC-complexed OVA peptide quantities were assessed using DOBW cells (1×10^5^/well), which recognize OVA\[323-339\]-I-A^d^ complexes and secrete IL-2 ([@B19]).

Statistical analysis
--------------------

The statistical significance of the difference between the control and treatment groups was assessed using a one-way ANOVA followed by a Student\'s t-test.

RESULTS
=======

VR1 agonists increase MHC class I-restricted OVA presentation in BM-DCs infected with VV-OVA
--------------------------------------------------------------------------------------------

To examine the effects of VR1 agonists on MHC class I-restricted endogenous antigen presentation, BM-DCs were infected with VV-OVA (MOI=5), and then cultured in the presence of different concentrations of CP or RTX. After 6 h, the cells were fixed with paraformaldehyde, washed, and then the amounts of MHC class I (K^b^)-OVA peptide complexes on the cell surface were assessed using CD8 OVA1.3 cells. Both CP and RTX increased MHC class I-restricted presentation of virus-encoded OVA ([Fig. 1A](#F1){ref-type="fig"}). The ability of CP and RTX to increase MHC class I-restricted endogenous antigen presentation reached near maximum levels at 32 nM and 6.4 nM, respectively, showing that RTX is much more potent than CP in increasing MHC class I-restricted endogenous antigen presentation in DCs.

VR1 agonists increase MHC class I-restricted DC presentation of OVA peptides in mice infected with VV-OVA
---------------------------------------------------------------------------------------------------------

To examine whether VR1 agonists also increase MHC class I-restricted endogenous antigen presentation *in vivo* , CP (10 mg/kg) or RTX (0.1 mg/kg) was orally administered to C57BL/6 mice for 3 days, followed by infection with VV-OVA (5×10^4^ CFUs/mouse, i.v.). After virus infection, the mice were orally administrated with the same doses of CP or RTX for consecutive 5 days. On the final day of VR1 agonist administration, DCs were isolated from the lymph nodes and spleens of the mice, and the amounts of K^b^-OVA peptide complexes on the cell surface were evaluated using OVA-specific CD8 T hybridoma cells (B3Z cells). Both CP and RTX significantly increased MHC class I-restricted presentation of virus-encoded OVA in both lymph node DCs and spleen DCs ([Fig. 1B, C](#F1){ref-type="fig"}).

The amounts of K^b^-OVA peptide complexes on the cell surface of lymph node and spleen DCs were directly determined using the F(ab\')2 fragment of a SIINFEKL-H-2K^b^-specific mAb (25-D1.16). Oral administration of CP and RTX ([Fig. 2A](#F2){ref-type="fig"}) profoundly increased the cell surface expression of SIINFEKL-H-2K^b^ complexes in the spleen DCs of VV-OVA-infected mice. We then examined whether CP and RTX increased the expression of MHC class I molecules on DCs. Both CP and RTX increased the expression levels of H-2K^b^ molecules, but not the expression levels of I-A^b^ molecules, in the spleen DCs of VV-OVA-infected mice ([Fig. 2B](#F2){ref-type="fig"}).

Oral administration of VR1 agonists increased OVA-specific CTL activity in mice infected with VV-OVA
----------------------------------------------------------------------------------------------------

The effects of VR1 agonists on the induction of CTL activity were examined in mice orally administered CP or RTX for 3 days, infected with VV-OVA, and then treated with the same doses of CP or RTX for consecutive 5 days, as described in [Fig. 1](#F1){ref-type="fig"}. On the final day of VR1 agonist administration, *in vivo* CTL assays were performed using CFSE-labeled syngeneic target cells. Representative histograms are shown in [Fig. 3](#F3){ref-type="fig"}. Oral administration of CP ([Fig. 3A](#F3){ref-type="fig"}) or RTX ([Fig. 3B](#F3){ref-type="fig"}) significantly increased OVA-specific CTL activities in the lymph nodes and spleens.

Oral CP administration increased the proliferation and activation of adaptively transferred OT-I cells
------------------------------------------------------------------------------------------------------

To confirm that CP increases MHC class I-restricted OVA presentation in DCs of VV-OVA infected mice, an adaptive transfer experiment was performed, in which OVA-specific CD8^+^ T cells (OT-I cells) were transferred to VV-OVA-infected mice. Mice were orally administered CP, infected with VV-OVA, and then treated with the same doses of CP for consecutive 5 days, as described in [Fig. 1](#F1){ref-type="fig"}. On the final day of CP administration, CFSE-labeled OT-I cells were injected through the tail vein. After 4 days, proliferation of OT-I cells in the spleens and lymph nodes was determined by the progressive dilution of CFSE intensity, as determined by flow cytometry. Representative histograms are shown in [Fig. 4](#F4){ref-type="fig"}. OT-1 cells in the lymph node and spleen expanded significantly in CP-treated mice, compared with vehicle-administered control mice.

To examine the effects of CP on IFN-γ production in CD8 T cells, total spleen cells and lymph node cells were isolated from mice treated with CP and adaptively transferred with OT-1 cells, and were re-stimulated with OVA~\[257-264\]~-SIINFEKL peptide-pulsed normal BM-DCs in the presence of monensin for 6 h. The cells were stained with an anti-CD8 mAb, permeabilized, and stained with an anti-IFN-γ mAb. Representative histograms are shown in [Fig. 5A](#F5){ref-type="fig"}. Oral administration of CP significantly increased the frequency of IFN-γ-producing CD8 T cells among total CD8 T cells ([Fig. 5B](#F5){ref-type="fig"}).

VR1 agonists increase class I, but not class II, MHC-restricted processing of exogenous antigen in BM-DCs
---------------------------------------------------------------------------------------------------------

The effects of VR1 agonists on the MHC-restricted exogenous antigen presentation were examined using BM-DCs. For MHC class I-restricted exogenous antigen presentation assays, BM-DCs were generated from BM cells of C57BL/6 mice, treated with the indicated concentrations of CP or RTX for 4 h, and then allowed to phagocytose OVA-microspheres for 2 h. The BM-DCs were washed and fixed with paraformaldehyde. Class I MHC-complexed OVA peptide quantities were assessed using CD8 OVA 1.3 hybriboma cells. The results showed that CP and RTX efficiently enhanced class I MHC-restricted exogenous OVA presentation ([Fig. 6A](#F6){ref-type="fig"}). For MHC class II-restricted exogenous antigen presentation assays, BM-DCs were generated from the BM cells of BALB/c mice, treated with the indicated concentrations of CP or RTX for 4 h, and then allowed to phagocytose OVA-microspheres for 2 h. The BM-DCs were washed and fixed with paraformaldehyde. Class II MHC-complexed OVA peptide quantities were assessed using DOBW cells. The results showed that CP and RTX did not affect class II MHC-restricted exogenous OVA presentation in BM-DCs ([Fig. 6B](#F6){ref-type="fig"}).

To test whether the class I MHC-restricted antigen presentation-enhancing activity of CP and RTX was due to the enhancement of phagocytic activity, BM-DCs generated from BM cells of C57BL/6 mice were incubated with FITC-labeled OVA-microspheres, washed, and then harvested by gentle pipetting after cooling on ice. Flow cytometric analysis of the harvested cells showed that CP and RTX did not affect the phagocytic activity of BM-DCs ([Fig. 6C, D](#F6){ref-type="fig"}).

DISCUSSION
==========

The major finding of the present study is that VR1 agonists, CP and RTX, enhance MHC class I-restricted viral antigen presentation in DCs infected with a virus. We used VV-OVA as a model virus to infect DCs. Both CP and RTX increased MHC class I (K^b^)-restricted OVA peptide presentation in BM-DCs infected with VV-OVA. The *in vivo* relevance of the enhancement of MHC class I-restricted endogenous antigen presentation was studied in mice orally administered a VR1 agonist and infected with VV-OVA, which showed that that both CP and RTX significantly increased MHC class I-restricted OVA peptide presentation *in vivo*. Consistent with these results, both CP and RTX increased the production of OVA-specific CTLs in mice infected with VV-OVA.

The results from numerous studies have shown that CP exerts anti-inflammatory properties mainly via inhibiting innate immune responses ([@B9][@B11][@B13]). CP can inhibit adaptive immune responses, such as lymphocyte proliferation and T cell differentiation ([@B8][@B12]), and reduce IgA and IgG production ([@B25]). In contrast, CP exerts adjuvant activity on antigen-specific T cell responses. For instance, when CP and OVA were co-injected into mice that were adaptively transferred with OVA-specific T cells (OT1 cells), CP increased OT1 cell proliferation and the generation of OVA-specific CTLs ([@B14]). This study could represent an indirect demonstration of the enhancing effect of CP on the MHC class I-restricted exogenous antigen presentation. In contrast to the effects of CP on MHC class I-restricted exogenous antigen presentation, CP was previously reported to inhibit MHC class II-restricted exogenous antigen presentation ([@B16]). CP inhibited IFN-γ-induced MHC class II expression by suppressing CIITA expression in macrophages. To date, the effects of CP on MHC class I-restricted endogenous antigen presentation has not been studied in detail. Here, we demonstrated that CP and RTX increase MHC class I-restricted endogenous antigen presentation in DCs both *in vitro* and *in vivo*. The MHC class I-restricted endogenous antigen presentation-enhancing activity of CP and RTX was confirmed by directly measuring OVA peptide SIINFEKL-K^b^ complexes on the cell surface and by performing functional assays using OVA-specific T cells. It is also noteworthy that CP and RTX were both administered orally in this study, whereas CP was injected intradermally in an experiment showing that CP increased the MHC class I-restricted exogenous antigen presentation ([@B14]).

Both CP and RTX increased MHC class I-restricted exogenous antigen presentation (cross-presentation), but did not affect MHC class II-restricted exogenous antigen presentation ([Fig. 6](#F6){ref-type="fig"}). The classical paradigm of antigen presentation by professional APCs is that endogenous antigens are presented via MHC-I molecules to CD8^+^ T cells, whereas exogenous antigens are presented via MHC-II molecules to CD4^+^ T cells ([@B26]). Subsequently, it was demonstrated that professional APCs also process exogenous antigens for presentation by MHC-I molecules to CD8^+^ T cells. This process was termed crosspresentation ([@B27][@B28][@B29]). The current study and the earlier study by Basu and Srivastava ([@B14]) demonstrated that CP increased the MHC class I-restricted antigen presentation of both exogenous and endogenous antigens. CP, however, inhibited MHC class II-restricted antigen presentation of exogenous antigens ([@B16]). The discrepancy in the effects of CP on MHC class II-restricted exogenous antigen presentation may due to differences in the cell type used and in the stimulation conditions. When examining the effects of CP on MHC class II-restricted exogenous antigen presentation, we used immature DCs, while Mahmoud et al. used IFN-γ-activated macrophages ([@B16]).

RTX is a much more potent VR1 agonist than is CP ([@B2]). In agreement, RTX was much more potent than CP in increasing MHC class I-restricted exogenous antigen presentation in DCs. When examining the effects of CP and RTX on the MHC class I-restricted endogenous antigen presentation *in vivo*, mice were fed with 10 mg/kg CP and 0.1 mg/kg RTX, and similar results were obtained in functional assays, such as *in vivo* CTL assays ([Fig. 3](#F3){ref-type="fig"}), OT1 cell-proliferation assays ([Fig. 4](#F4){ref-type="fig"}), and intracellular staining of IFN-γ-producing CD8 T cells ([Fig. 5](#F5){ref-type="fig"}). Thus, the potency of CP and RTX in increasing MHC class I-restricted endogenous antigen presentation appears to be directly proportional to the potency of VR1 receptor binding.
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![VR1 agonists increase MHC class I-restricted OVA presentation in DCs infected with VV-OVA. (A) BM-DCs (1×10^5^/well) generated from C57BL/6 (H-2^b^) mice were infected with VV-OVA (MOI=5), and cultured for 6 h in the presence of the indicated amounts of CP or RTX. The amounts of H-2K^b^-OVA peptide complexes were assessed using CD8 OVA1.3 cells. (B, C) VR1 agonists increased MHC class I-restricted DC presentation of OVA peptides in mice infected with VV-OVA. C57BL/6 mice were orally administered CP (10 mg/kg) or RTX (0.1 mg/kg) was for 3 days, and then then were infected with VV-OVA (5×10^4^ CFUs/mouse, i.v.). After virus infection, the mice were orally administrated the same doses of CP or RTX for consecutive 5 days. On the final day of VR1 agonist administration, DCs were isolated from the lymph nodes and spleens of the mice, and the amounts of K^b^-OVA peptide complexes on the cell surface were evaluated using OVA-specific CD8 T hybridoma cells (B3Z cells). ^\*\*^p\<0.01.](in-16-233-g001){#F1}

![VR1 agonists increased the expression of SIINFEKL-H-2K^b^ complexes in mice infected with VV-OVA. Mice were orally administered CP or RTX for 3 days, infected with VV-OVA, and then treated with the same doses of CP or RTX for consecutive 5 days, as described in [Fig. 1](#F1){ref-type="fig"}. DCs were isolated from the lymph nodes and spleens. (A) The amounts of K^b^-OVA peptide complexes on the cell surface were directly determined using the F(ab\')2 fragment of a SIINFEKL-H-2K^b^-specific mAb (25-D1.16). (B) Expression levels of H-2K^b^ and I-A^b^ molecules. Blue dotted line, isotype control; green shaded area, DCs from mice not treated with a VR1 agonist (CP or RTX); red line, DCs from VR1 agonist-treated mouse.](in-16-233-g002){#F2}

![VR1 agonists increased OVA-specific CTL activity in mice injected with VV-OVA. Mice were orally administered CP or RTX for 3 days, infected with VV-OVA, and then treated with the same doses of CP or RTX for consecutive 5 days, as described in [Fig. 1](#F1){ref-type="fig"}. On the final day of VR1 agonist administration, and *in vivo* CTL assays were performed using CFSE-labeled syngeneic target cells. (A) Representative histograms of lymph node and spleen cells, and the percentage of specific killing of OVA\[257-264\] peptide-pulsed target cells in the lymph nodes and spleens are shown (n=5 for each group). Each data point represents the mean±SD of values obtained from 2 individual experiments. ^\*^p\<0.05; ^\*\*^p\<0.01.](in-16-233-g003){#F3}

![CP increased the proliferation of adaptively transferred OTI cells. Mice were orally administered CP, infected with VV-OVA, and then treated with the same doses of CP for consecutive 5 days, as described in [Fig. 1](#F1){ref-type="fig"}. On the final day of CP administration, CFSE-labeled OT-I cells were injected through the tail vein. After 4 days, proliferation of OT-I cells in the spleens and lymph nodes was determined by flow cytometry.](in-16-233-g004){#F4}

![CP increased IFN-γ producing CD8 T cells in mice infected with rVV-OVA. Mice were orally administered CP, infected with VV-OVA, and then treated with the same doses of CP for consecutive 5 days, as described in [Fig. 1](#F1){ref-type="fig"}. On the final day of CP administration, CFSE-labeled OT-I cells were injected through the tail vein. After 4 days, the lymph node and spleen cells were isolated and restimulated for 6 h with OVA\[257-264\] peptide-pulsed DCs. The cells were stained with an anti-CD8 mAb, then permeabilized and stained with an anti-IFN-γ mAb. (A) Representative histograms are shown. (B) The percentages of IFN-γ^+^ cells among total CD8^+^ T cells are shown graphically (n=5 for each group). ^\*\*^p\<0.01.](in-16-233-g005){#F5}

![VR1 agonists increases class I, but not class II, MHC-restricted presentation of exogenous antigen in BM-DCs. (A) BM-DCs generated from BM cells of C57BL/6 mice were treated with the indicated concentrations of CP or RTX for 4 h, and then allowed to phagocytose OVA-microspheres for 2 h. After fixing, the amounts of H-2K^b^-OVA peptide complexes were assessed using CD8 OVA 1.3 cells. (B) BM-DCs generated from BM cells of BALB/c mice were treated with the indicated concentrations of CP or RTX for 4 h, and then allowed to phagocytose OVA-microspheres for 2 h. After fixing, the amounts of I-A^d^-OVA peptide complexes were assessed using DOBW cells. (C, D) Effects of CP and RTX on phagocytic activity. BM-DCs generated from BM cells of C57BL/6 mice were incubated with FITC-labeled OVA-microspheres, washed, harvested, and analyzed by flow cytometry. A representative set of histograms from 3 individual experiments is shown. Shaded histograms, phagocytic activity of DCs in the absence of CP or RTX; thick line histograms, phagocytic activity of DCs in the presence of CP or RTX.](in-16-233-g006){#F6}
